Cranleigh, United Kingdom

Noel A Mullen

This inventor holds 1 USPTO granted patent. Top assignee: Beecham Group Plc. Active years: 1982.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Noel A Mullen. Retrieved from https://idiyas.com/inventor/noel-a-mullen

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 2.0

ph-index = 1

Forward Citations = 8(Granted Patents)


Company Filing History:


Years Active: 1982

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Noel A Mullen

Introduction

Noel A Mullen is a notable inventor based in Cranleigh, GB. He has made significant contributions to the field of medical treatments, particularly in addressing diarrhoea. His innovative approach has led to the development of a unique patent that showcases his expertise and dedication to improving health outcomes.

Latest Patents

Noel A Mullen holds a patent for the "Treatment of diarrhoea - Vasoconstrictor .alpha.-adrenergic agonists of formula (I)." This patent represents a significant advancement in the treatment options available for diarrhoea, highlighting Mullen's commitment to addressing critical health issues.

Career Highlights

Mullen is associated with Beecham Group Plc, a company known for its contributions to pharmaceuticals and healthcare. His work at Beecham Group Plc has allowed him to collaborate with other professionals in the field, further enhancing his impact on medical innovations.

Collaborations

One of his notable coworkers is Peter M Newsome. Their collaboration has likely contributed to the development of innovative solutions in the medical field, although specific details of their joint efforts are not provided.

Conclusion

Noel A Mullen's contributions to medical innovation, particularly through his patent for treating diarrhoea, underscore his role as a significant inventor in the healthcare sector. His work continues to influence the development of effective treatments for critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…